Report Keywords – CAR-T, Cell Therapies,Therapies Market, Roots Analysis, Report, Biotech
RootsAnalysis has announced the addition of “CAR-T Cell Therapies Market (3rd Edition) by Target Indications (NHL, MultipleMyeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, FollicularLymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), TargetAntigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and KeyGeographies (North America, Europe, Asia Pacific, Latin America, Middle Eastand North Africa, and Rest of the World) – Industry Trends and GlobalForecasts, 2021-2030” report to its list of offerings.
Given their ability to selectively direct a cell mediatedimmune response against cancer cells and, thereby, offer prolonged periods ofdisease remission, several CAR-T cell therapies provide a promising therapeuticstrategy for advanced stage cancers and are expected to achieve blockbuster status.With four approved products and many candidate therapies under evaluation forthe treatment of multiple disease indications, the CAR-T cell therapy market ischaracterized by a healthy and growing pipeline. Further, with lucrativefinancial support and notable increase in partnerships, the CAR-T-celltherapies market is abuzz with activity.
To order this 795+ page report, which features165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html
Key Market Insights
Over 755 CAR-T celltherapies are currently approved/ under development
Close to 40% of the aforementioned candidates are inpreclinical and discovery stages, while more than 25% are being evaluated inclinical stages (phase I/II and above). Examples of late-stage clinicalcandidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T /JNJ-68284528.
Currently, the focus is on developing product candidates totreat various types of cancers
Over 95% of the products in the development pipeline arebeing evaluated for the treatment of hematological malignancies, including (indecreasing order of number of pipeline products) acute lymphoblasticleukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia.Only 2% of current pipeline candidates are being developed for the treatment ofnon-oncological indications.
Extensive efforts are underway to improve CAR constructs
Majority of theproduct candidates in the clinical pipeline, including the four approved drugproducts, are based on second generation CARs. Further, a number of novel therapies armed with fourthgeneration CAR constructs, CAR-based products containing humanized scFv andbispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluatedworldwide.
China is leading the product development efforts related toCAR-T cell therapies, in terms of number of active trials and supportinghospitals
In the last 10 years, over half of the 410 clinical trialsevaluating various types of CAR-T cell therapies, were registered in China. Inaddition, owning to a favorable clinical research environment, China ispresently considered to be among the leading regions in the CAR-T cell therapyspace, with close to 40 industry players and more than 100 non-industryplayers, including hospitals and universities, contributing to this field.
Partnership activitywithin this domain has grown at a CAGR of 26%, between 2011 and 2020
More than 220 agreements were inked related to CAR-T celltherapies, with the maximum activity being reported in 2018. Majority ofpartnership deals signed within this domain were R&D agreements (21%),technology licensing (20%) and product development and commercializationagreements (11%).
Over USD 13 billion has been invested by both private andpublic investors, across more than 205 instances
It is important to mention that, between 2013 and 2020,majority of the funding was acquired through venture capital rounds (37%),other equity financing elements (24%), grants (12%) and secondary offerings(12%).
The market is anticipated to grow at a CAGR of over 28%,during the period 2021-2030
Growth in this domainis anticipated to be primarily driven by encouraging clinical trial results andthe recent success of the four approved CAR-T cell therapies. North America (primarilythe US) and Europe are expected to capture over 75% of the market share by2030, in terms of the sales-based revenues.
To request a sample copy / brochure ofthis report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html
KeyQuestions Answered
§ Who are the leading industry and non-industry players inthis market?
§ Whatare the prevalent R&D trends in CAR-T cell therapies domain?
§ Whatare the key therapeutic areas for which CAR-T cell therapies are being / havebeen developed?
§ Whatare the challenges faced by stakeholders in this industry?
§ Whichare the key geographies where extensive research on CAR-T cell therapies isbeing conducted?
§ Whoare the key investors in this domain?
§ Whoare the key opinion leaders / experts that can help in driving productdevelopment efforts in this field?
§ Whatkind of partnership models are commonly adopted by industry stakeholders?
§ Whatkind of contract manufacturing support is available for CAR-T cell therapies?
§ Whatkind of promotional strategies are likely to be adopted for CAR-T celltherapies that are approved / commercialized in future?
§ Whatare the factors that are likely to influence the evolution of this upcomingmarket?
§ How is the current and future market opportunity likely tobe distributed across key market segments?
The USD 14 billion (by 2030) financial opportunitywithin the CAR-T cell therapy market has been analyzed across the followingsegments:
§ Disease indication
§ Non-Hodgkinlymphoma
§ Multiplemyeloma
§ Chroniclymphocytic leukemia
§ Acutelymphoblastic leukemia
§ Follicularlymphoma
§ Mantlecell lymphoma
§ Hepatocellularcarcinoma
§ Colorectalcancer
§ Targetantigens
§ CD19
§ BCMA
§ CD19,CD22
§ GPC3
§ EGFR
§ KeyGeographical Regions
§ NorthAmerica
§ Europe
§ AsiaPacific
§ LatinAmerica
§ MiddleEast and North Africa
§ Restof the World
The report features inputs from eminent industrystakeholders, according to whom CAR-T cell therapies are soon likely to witnessincreased adoption given their broad scope of applications in various advancedstage oncological disorders. The report includes detailed transcriptsof discussions held with the following experts:
§ Tim Oldham (Chief Executive Officer, Cell Therapies)
§ Troels Jordansen (Chief Executive Officer, GlycostemTherapeutics)
§ Wei (William) Cao (Co-Founder, Chairman and Chief ExecutiveOfficer, Gracell Biotechnologies)
§ Miguel Forte (Chief Operating Officer, TxCell)
§ Adrian Bot (Vice President, Scientific Affairs, KitePharma)
§ Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
§ Brian Dattilo (Manager of Business Development, WaismanBiomanufacturing)
§ Aino Kalervo (Competitive Intelligence Manager, Strategy& Business Development, Theravectys)
§ Xian-Bao Zhan (Professor of Medicine and Director,Department of Oncology, Changhai Hospital)
§ Enkhtsetseg Purev (Assistant Professor of Medicine,University of Colorado)
The research includes brief profiles, featuring an overviewof the company, its financial information (if available), and a description ofits product(s), highlighting type of therapy and current development status.Each company profile includes technology portfolio (if available), recentdevelopments related to T-cell immunotherapies and manufacturing capabilitiesof the companies.
§ Autolus
§ bluebird bio
§ CARsgen Therapeutics
§ Celgene (A Bristol Myers Squibb Company)
§ Cellectis
§ Cellular Biomedicine Group
§ Innovative Cellular Therapeutics
§ Iovance Biotherapeutics
§ Kite Pharma (A Gilead Sciences Company)
§ Kuur Therapeutics
§ Noile-Immune Biotech
§ Novartis
§ Shanghai Genechem
§ Sinobioway Cell Therapy
§ Takara Bio
§ Ziopharm Oncology
For additionaldetails, please visit
https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html oremail sales@rootsanalysis.com
You may also beinterested in the following titles:
1. Global T-Cell Therapies Market (5thEdition), 2021 – 2030
2. mRNA Therapeutics andVaccines Market, 2020-2030
3. Gene Therapies Market (4th Edition):Industry Trends and Global Forecasts, 2020-2030
4. Oncolytic Virus Therapy Market:Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
